Diaceutics shares edge higher as company on track for full-year profitability

Published 23/09/2025, 09:44
 Diaceutics shares edge higher as company on track for full-year profitability

Investing.com - Diaceutics PLC (AIM:DXRX) shares rose 0.9% after the precision medicine commercialization partner reported strong first-half 2025 results, with revenue growth of 22% on a constant currency basis to £14.6 million and a return to adjusted EBITDA profitability.

The company, which provides data analytics and commercialization solutions to pharmaceutical and biotech firms, reported H1 adjusted EBITDA of £0.1 million compared to a £0.9 million loss in the same period last year.

This marks an important milestone as Diaceutics confirmed it remains on track to deliver full-year profitability for 2025.

Revenue growth was driven by increasing adoption of the company’s DXRX platform, with recurring revenue now representing 61% of total H1 revenues, up from 55% a year earlier.

Annual Recurring Revenue (ARR) increased 16% to £16.4 million, while the company’s order book grew 14% to £31.7 million, with £9.0 million already contracted for delivery in the second half of 2025.

"I am extremely pleased to report another period of strong operational and commercial execution, marked by double-digit organic revenue growth, expanding customer adoption and increased recurring revenue visibility," said Ryan Keeling, Diaceutics’ Chief Executive Officer.

"The success of our current strategy and financial strength, and the sustained positive momentum in 2025 to date, serve to validate our growth strategy and provide us with confidence that our profitability targets for 2025 are on track to be delivered as we continue to grow."

The company reported a 17% increase in the number of therapeutic brands it works with, reaching 74 in H1 2025 compared to 63 in the same period last year. Diaceutics also secured a new enterprise-wide agreement, bringing its total to eight, representing £10.1 million in ARR.

Despite a challenging environment for the pharmaceutical industry, particularly in the US market, Diaceutics maintained a strong balance sheet with no debt and cash of £10.4 million at the end of June 2025.

The company expects to maintain its momentum in the second half of the year, with continued focus on deeper customer engagement and leveraging its enhanced technologies to deliver operational leverage.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.